Initiator Pharma Q1: Slow and steady - Redeye

Redeye provides a research update following the Q1 report recently published by Initiator Pharma. While the company is still awaiting a licensing deal with pudafensine before engaging in further clinical activities, Initiator maintains a very low cash burn. As we have previously stated, the company’s full priority ahead is business development efforts as Initiator continues its pursuit of a licensing partner.

Länk till analysen i sin helhet: https://www.redeye.se/research/1107127/initiator-pharma-q1-slow-and-steady?utm_source=finwire&utm_medium=RSS